Do we know the optimal dose for renal replacement therapy in the intensive care unit?

Research output: Contribution to journalComment / DebateOtherpeer-review

38 Citations (Scopus)

Abstract

Increasing the dose of renal replacement therapy might increase survival in critically ill patients with acute renal failure. For continuous renal replacement therapy (CRRT), a single-center study suggests that increasing urea clearance from 20 ml/kg/h to 35-45 ml/kg/h might increase short-term survival. A further single-center study has now confirmed that the dose of CRRT might be a determinant of outcome. This issue is now being addressed by two large multicenter randomized controlled trials in the United States (the ATN study) and Australia and New Zealand (the RENAL study). The results of these two studies should be available in 2008. Before making any major changes to practice, it seems prudent to wait for the publication of the findings of these two pivotal trials.

Original languageEnglish
Pages (from-to)1202-1204
Number of pages3
JournalKidney International
Volume70
Issue number7
DOIs
Publication statusPublished - 9 Oct 2006
Externally publishedYes

Cite this

@article{f262ddc2512b4e9787c1ca48f0d6d1ed,
title = "Do we know the optimal dose for renal replacement therapy in the intensive care unit?",
abstract = "Increasing the dose of renal replacement therapy might increase survival in critically ill patients with acute renal failure. For continuous renal replacement therapy (CRRT), a single-center study suggests that increasing urea clearance from 20 ml/kg/h to 35-45 ml/kg/h might increase short-term survival. A further single-center study has now confirmed that the dose of CRRT might be a determinant of outcome. This issue is now being addressed by two large multicenter randomized controlled trials in the United States (the ATN study) and Australia and New Zealand (the RENAL study). The results of these two studies should be available in 2008. Before making any major changes to practice, it seems prudent to wait for the publication of the findings of these two pivotal trials.",
author = "R. Bellomo",
year = "2006",
month = "10",
day = "9",
doi = "10.1038/sj.ki.5001827",
language = "English",
volume = "70",
pages = "1202--1204",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Elsevier",
number = "7",

}

Do we know the optimal dose for renal replacement therapy in the intensive care unit? / Bellomo, R.

In: Kidney International, Vol. 70, No. 7, 09.10.2006, p. 1202-1204.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Do we know the optimal dose for renal replacement therapy in the intensive care unit?

AU - Bellomo, R.

PY - 2006/10/9

Y1 - 2006/10/9

N2 - Increasing the dose of renal replacement therapy might increase survival in critically ill patients with acute renal failure. For continuous renal replacement therapy (CRRT), a single-center study suggests that increasing urea clearance from 20 ml/kg/h to 35-45 ml/kg/h might increase short-term survival. A further single-center study has now confirmed that the dose of CRRT might be a determinant of outcome. This issue is now being addressed by two large multicenter randomized controlled trials in the United States (the ATN study) and Australia and New Zealand (the RENAL study). The results of these two studies should be available in 2008. Before making any major changes to practice, it seems prudent to wait for the publication of the findings of these two pivotal trials.

AB - Increasing the dose of renal replacement therapy might increase survival in critically ill patients with acute renal failure. For continuous renal replacement therapy (CRRT), a single-center study suggests that increasing urea clearance from 20 ml/kg/h to 35-45 ml/kg/h might increase short-term survival. A further single-center study has now confirmed that the dose of CRRT might be a determinant of outcome. This issue is now being addressed by two large multicenter randomized controlled trials in the United States (the ATN study) and Australia and New Zealand (the RENAL study). The results of these two studies should be available in 2008. Before making any major changes to practice, it seems prudent to wait for the publication of the findings of these two pivotal trials.

UR - http://www.scopus.com/inward/record.url?scp=33748941086&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5001827

DO - 10.1038/sj.ki.5001827

M3 - Comment / Debate

C2 - 16988729

AN - SCOPUS:33748941086

VL - 70

SP - 1202

EP - 1204

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 7

ER -